Editorial: Steroid hormone receptors and cell cycle in breast cancer

Abstract

Breast cancer is the most frequently diagnosed cancer in women with a high incidence and mortality worldwide. Nearly 70% of breast carcinomas express steroid hormone receptors and therefore patients can be treated with endocrine therapy. The treatment is principally targeted to block the estrogen receptor (ER) or estrogen synthesis (1). However, increasing evidence also suggests that the progesterone receptor (PR) is a potential target for therapy (2).